Otezla Acquisition


Amgen, an SJE Group investment, has completed its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis.


Otezla is an important treatment in the post-topical, pre-biologic segment in its approved indications in the U.S., including the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy; adult patients with active psoriatic arthritis; and adult patients with oral ulcers associated with Behçet's Disease.


Otezla is approved in more than 50 markets outside the U.S., including the European Union and Japan.

© 2019 by SJE Group. Proudly created by DMC Solutions.

Argentina. Austria. Australia. Bahamas. Belgium. Belize. Bermuda. Brazil. Canada. China. Colombia. Denmark. Finland. France. Germany. Hong Kong. Indonesia. Ireland. Israel. Italy. Japan. Luxembourg. Malaysia. Mexico. Monaco. Netherlands. New Zealand. Nigeria. Norway. Philippines. Poland. Portugal. Singapore. South Africa. South Korea. Spain. Sweden. Switzerland. Thailand. Turkey. UAE. UK. US.